NCT07049185尚未招募2 期
A Single-Arm Clinical Trial of QL1706 Combined With Celecoxib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Prior ICI Therapy
Peking University Cancer Hospital & Institute0 个研究点目标入组 35 人开始时间: 2025年7月15日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 35
- 主要终点
- Objective Response Rate (ORR) as assessed by RECIST v1.1
研究概览
简要总结
This is a single-arm, Simon's two-stage phase II clinical trial to evaluate the efficacy and safety of QL1706 (a dual PD-1 and CTLA-4 antibody) combined with celecoxib in patients with advanced esophageal squamous cell carcinoma (ESCC) who progressed after prior immune checkpoint inhibitor therapy.
详细描述
The study aims to explore whether the combination of QL1706 and celecoxib can improve the objective response rate in ICI-refractory ESCC. Eligible patients will receive QL1706 (5 mg/kg IV Q3W) and celecoxib (200 mg BID orally) until disease progression, unacceptable toxicity, or up to 2 years. Safety, PFS, OS, and biomarkers such as PD-L1, HER2, IL-6, and IL-8 will also be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide written informed consent;
- •Aged 18 to 75 years, inclusive;
- •Histologically or cytologically confirmed unresectable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC);
- •Radiologically confirmed disease progression after at least 6 months of prior PD-1/PD-L1 inhibitor-based treatment;
- •At least one measurable lesion per RECIST v1.1 criteria;
- •Ability to swallow oral medication;
- •ECOG performance status of 0-1;
- •Estimated life expectancy ≥12 weeks;
- •Adequate organ function (without blood transfusion or growth factors within 14 days prior to first dose), including:
- •ANC ≥ 1.5 × 10⁹/L; Platelets ≥ 100 × 10⁹/L; Hemoglobin ≥ 90 g/L; Serum albumin ≥ 30 g/L; TSH ≤ ULN; if abnormal, normal FT3/FT4 is acceptable; Total bilirubin ≤ 1.5 × ULN; ALT/AST ≤ 2.5 × ULN (≤ 5 × ULN if with liver metastases); ALP ≤ 2.5 × ULN; Serum creatinine ≤ 1.5 × ULN or CrCl ≥ 50 mL/min; INR ≤ 1.5 (if not on anticoagulation);
- •Non-sterilized women of childbearing potential and male participants with such partners must agree to use medically approved contraception during and for 3 months after study drug administration. Women must test negative for serum or urine HCG within 7 days prior to first dose and not be breastfeeding.
- •Exclusion Criteria：
- •Any active autoimmune disease or history of autoimmune disease (e.g., autoimmune hepatitis, interstitial pneumonia, uveitis, colitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism); exceptions: childhood asthma fully resolved without treatment or vitiligo;
- •Currently using immunosuppressive therapy or systemic corticosteroids >10 mg prednisone/day (or equivalent) within 2 weeks prior to enrollment;
- •History of severe allergic reactions to monoclonal antibodies;
- •Discontinued prior PD-1/PD-L1 therapy due to treatment-related toxicity;
- •Prior exposure to anti-CTLA-4 therapy;
- •History or evidence of interstitial lung disease or active non-infectious pneumonitis;
- •Known active tuberculosis;
- •Known CNS metastases, leptomeningeal disease, or spinal cord compression;
- •Other malignancies within 5 years (excluding cured skin basal cell carcinoma or cervical carcinoma in situ);
- •Clinically significant cardiac conditions (NYHA ≥ Class II heart failure, unstable angina, MI within 1 year, clinically significant arrhythmias requiring treatment, QTc >450 ms for males or >470 ms for females);
- •Clinically significant bleeding within 3 months before enrollment or known bleeding tendency (positive fecal occult blood must be followed by endoscopy if persistent);
- •Tumor invading major blood vessels or deemed likely to invade during the study;
- •Patients with esophagotracheal or mediastinal fistulas;
- •Clinically significant pleural/ascitic/pericardial effusion requiring drainage (if resolved and stable after drainage, enrollment is allowed);
- •Arterial or venous thrombotic events within 6 months (e.g., stroke, DVT, PE);
- •Known congenital or acquired bleeding disorders;
- •Abdominal fistula, GI perforation, or intra-abdominal abscess within 6 months;
- •Prior radiotherapy, chemotherapy, or surgery within 4 weeks prior to first study dose (except bone metastasis palliative radiotherapy); biologics within 4 weeks; targeted therapy within 5 half-lives; unresolved toxicities ≥ Grade 2 (except alopecia);
- •Active infection or unexplained fever ≥38.5℃ within 7 days prior to first dose;
- •Known immunodeficiency (e.g., HIV); active HBV (HBsAg-positive with HBV DNA ≥ 2000 IU/mL); or active HCV infection;
- •Prior dual immunotherapy with PD-1 and CTLA-4 antibodies;
- •Significant bleeding history within 1 month (e.g., GI bleeding or vasculitis);
- •Live vaccine administration within 4 weeks prior to or planned during the study;
- •Other conditions deemed by the investigator to interfere with participation or study results (e.g., substance abuse, psychiatric disorders, severe lab abnormalities, or social/family limitations).
排除标准
- 未提供
研究组 & 干预措施
Combination Therapy Group
Experimental
QL1706 Plus Celecoxib Group
干预措施: QL1706 Plus Celecoxib Group (Drug)
结局指标
主要结局
Objective Response Rate (ORR) as assessed by RECIST v1.1
时间窗: Up to 24 weeks from first dose
Objective Response Rate (ORR) per RECIST v1.1 at 6 months
次要结局
- Overall Survival (OS)(1 year)
- Time to Response (TTR)(1 year)
- Disease Control Rate (DCR)(1 year)
- Progression-Free Survival (PFS)(1 year)
- Duration of Response (DOR)(1 year)
- Safety Assessment(1 year)
研究者
相似试验
招募中
1 期
QL1706 Combined With SOX Used in Theperioperative TreatmentGastric CancersEsophagogastric Junction CancersNCT06766305Xiangdong Cheng54
Unknown
2 期
Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical CancerCervical CancerNCT05179317Qilu Pharmaceutical Co., Ltd.60
尚未招募
3 期
a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.NCT06789796Qilu Pharmaceutical Co., Ltd.636
Unknown
2 期
A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical CancerUterine Cervical NeoplasmsSintilimabNCT05105672The Affiliated Hospital of Xuzhou Medical University20
招募中
2 期
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRCColorectal CarcinomaNCT05799820Qilu Pharmaceutical Co., Ltd.60